Sharon Li

ORCID: 0000-0002-1372-6631
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Colorectal Cancer Treatments and Studies
  • Gastric Cancer Management and Outcomes
  • Multiple and Secondary Primary Cancers
  • Pancreatic and Hepatic Oncology Research
  • Neuroendocrine Tumor Research Advances
  • Bone Tumor Diagnosis and Treatments
  • Pancreatitis Pathology and Treatment
  • Gastrointestinal Tumor Research and Treatment
  • Lung Cancer Research Studies
  • PI3K/AKT/mTOR signaling in cancer
  • Renal cell carcinoma treatment
  • Tumors and Oncological Cases
  • Cancer Genomics and Diagnostics
  • Sarcoma Diagnosis and Treatment
  • Advances in Oncology and Radiotherapy
  • Genetic factors in colorectal cancer
  • Genetics, Bioinformatics, and Biomedical Research
  • Lung Cancer Treatments and Mutations
  • Chronic Lymphocytic Leukemia Research
  • Metastasis and carcinoma case studies

Rutgers Cancer Institute of New Jersey
2021-2025

Rutgers, The State University of New Jersey
2021-2025

Rutgers New Jersey Medical School
2022-2024

University Hospital, Newark
2023-2024

Johnson University
2021

189 Background: TAS102 (trifluridine/tipiracil hydrochloride) is approved for use alone or with bevacizumab in late line metastatic colorectal cancer (mCRC), overall survival benefit phase 3 trials (RECOURSE and SUNLIGHT). Oxaliplatin frequently reintroduced after progression, resolution of limiting neuropathy, disease recurrence post adjuvant therapy. In preclinical studies, oxaliplatin combined has shown synergism. We hypothesized TASOX may be an option patients who have...

10.1200/jco.2025.43.4_suppl.189 article EN Journal of Clinical Oncology 2025-01-27

Across the nation, patients with locally advanced gastric cancer (LAGC) are managed modalities including upfront surgery (US) and perioperative chemotherapy (PCT). Preoperative therapies have demonstrated survival benefits over US thus long-term outcomes expected to vary between options. However, as these 2 continue be regularly employed, we sought perform a decision analysis comparing costs quality-of-life associated treatment of LAGC identify most cost-effective option. We designed tree...

10.1177/00031348241227180 article EN The American Surgeon 2024-01-15

There have been rare reports of patients developing nephrotic syndrome and thrombotic microangiopathy (TMA) with tyrosine kinase inhibitors (TKIs). We present the case a patient history metastatic pancreatic neuroendocrine tumor (pNET), treated sunitinib, who rapidly developed TMA acute kidney injury. The was successfully cessation sunitinib administration steroids. This report contributes to growing body literature surrounding side effects TKIs our experience management these adverse events.

10.7759/cureus.56660 article EN Cureus 2024-03-21

Pancreatic cancer (PC) has an overall 5-year survival rate of 10%. The use neoadjuvant chemoradiation is debated in resectable disease. purpose this study to evaluate the cost-effectiveness followed by pancreaticoduodenectomy (NACRT) versus upfront and adjuvant chemotherapy (USR) PC.A decision tree model was used estimate NACRT USR. Values from published literature populate tree: costs Medicare (FY2021) reimbursements, morbidity data for quality-adjusted life-years (QALYs). Patients with...

10.1200/op.22.00536 article EN JCO Oncology Practice 2022-12-22

e16065 Background: Across the nation, patients with locally advanced gastric cancer (LAGC) are managed modalities including upfront surgery (US), neoadjuvant chemoradiation therapy (NCRT), and perioperative chemotherapy (PCT). Treatment themselves associated adverse effects which can lead to difficulty treatment adherence in short-term. As preoperative therapies have demonstrated survival benefits over US, long-term outcomes expected vary, but it is not known if differences impacts...

10.1200/jco.2023.41.16_suppl.e16065 article EN Journal of Clinical Oncology 2023-06-01

e15515 Background: Colorectal cancers (CRC) with pathogenic mutations in POLE (mPOLE) represent a unique subgroup distinct clinical and molecular features may exhibit robust response to immune checkpoint blockade. Due low prevalence, of this remain incompletely characterized. Methods: We utilized data from the Oncology Research Information Exchange Network (ORIEN) , using Total Cancer Care (TCC) protocol 18 centers across US, identify mPOLE CRC cases through October 2020. Prevalence, genomic...

10.1200/jco.2021.39.15_suppl.e15515 article EN Journal of Clinical Oncology 2021-05-20

Abstract Purpose: Oncologic emergencies contribute to a large proportion of morbidity and mortality for oncology patients, who present unique medical challenges due disease treatment complexities. Emergencies training staff is important, particularly if there high turnover. We describe the development implementation program enhance timely recognition oncologic emergencies. Due COVID19 pandemic, sessions were conducted virtually. Methods: Healthcare workers normally care patients at Princess...

10.1158/1538-7755.asgcr21-84 article EN Cancer Epidemiology Biomarkers & Prevention 2021-07-01
Coming Soon ...